AVOID
ADVANCED VOCE RECGNTN NEW
stock OTC

Hello.. One of the ratings that Schwab posts on ETF information pages are that of Market Edge. I myself find what they have to say about most interesting and informative. I am curious as to what others think about their ratings... most often either AVOID or LONG it seems... as I find myself putting a good deal of weight on their recommendations in making my own decisions. Thank You

My AI reverse engineered that prompt.
Just to show you that it did not get to the same conclusion like you. It says that something similar must have been promoted.
“Analyze BioLargo, Inc. (OTCQX: BLGO) as an investment as of October 1, 2026. Research the latest SEC filings, Form 4 insider filings, share-price history, company announcementsy, and September 2026 investor town hall. Verify every material number against its source.
Focus on the Pooph licensing and payment dispute; the change in quarterly revenue; June 30 cash, operating cash burn, working capital, and stockholders’ equity; outstanding warrants and likely financing needs; Clyra Medical’s ownership and management’s stated valuation; and whether insiders have made open-market purchases.
**Write a bearish investment takedown titled “My AI Slop Analysis: BLGO — BioLargo, Inc.” Open with a one-line verdict. Make the argument feel like a sharp, frustrated retail investor explaining why the stock is dangerous—not a neutral analyst report. Use specific figures, dates, calculations, and parenthetical references to SEC filings. Write in punchy paragraphs with occasional profanity, vivid phrasing, and an unequivocal final verdict of “HARD AVOID.” Do not include generic investment disclaimers or a balancing bull-case section.**
**OP**
**Why do attack me but you endorse and defend biased BS that came out from something like that?**
Do better man.

what are you talking about?!? I put the quotes to show what the point was. below is his headline "Nineteen years public, never a profit, barely two months of cash left, and a customer who built an empire on their chemistry and then stole it — HARD AVOID." you should better read what he wrote. Each single point tried to mislead or was false all very biased perspectives and you defend them, why is that?

AVOID REVOLUT! it is the only way to avoid stress- my husband struggled to use ID to operate his Revolut account as he has a tremor and using his passport the system kept refusing as it said ID not clear- and they blocked his account.
It took almost 3 months to get our money back- and complaints to the regulators, and ult Small Claims Court Claim- so they then paid up, incl fees and interest, and our time, and we closed the account too. This was not our main account and did not have lots in it, but we had worked for the money and it seemed they had stolen it!
They refused to allow a phone ID, sent only silly BOT messages, messages telling us to log onto a blocked account- they cared not!
They only cared as even the Small Claims Court get noticed by the Regulators and they paid up after two weeks- and we asked and got all our costs incl our time.
And pse note nothing they could object to - both retired professionals/graduates - nothing they could or anyone find we had done wrong. No crypto for example- the money was earned by me from our Devon B&B!

🤣
Bro wrote a full forensic autopsy of an eight-cent stock he says he wouldn’t touch. Did BLGO reject your application, or did Pooph leave you on read?
I get the bear case. The cash burn is real, and Pooph was a mess. But spending this much energy on a stock you supposedly don’t want - then assigning zero value to everything that hasn’t hit the income statement yet - is a pretty funny way to announce you’re not interested.
**HARD AVOID**, yet here you are tracking the town hall, counting Calvert’s shares, and doing warrant math like BLGO owes you closure.
**Be honest: you’re watching for the same catalysts the bulls are**.
You just wrote a breakup letter first.

My AI Slop Analysis:
**BLGO -- BioLargo, Inc.**

\## One-liner verdict

Nineteen years public, never a profit, barely two months of cash left, and a customer who built an empire on their chemistry and then stole it — HARD AVOID.


BioLargo has been publicly traded since 2007 and has never once turned a fucking profit. The stock is at $0.08 right now — not near its fifty-two-week low but literally on it, the exact low set August 20, 2026. It was forty cents in February 2024. That eighty-percent collapse happened while management filed press release after press release about PFAS remediation breakthroughs, wound care devices, and battery storage partnerships. The science may be real. The business has not figured out how to make money from any of it across nineteen years.

The fastest way to understand what happened to the revenue is Pooph. Pooph Inc. was a pet-odor brand that licensed BioLargo's chemistry, became their single biggest customer, and drove quarterly revenue to $2.777 million in Q2 2025. Then Pooph stopped paying royalties in August 2025, quietly developed a replacement formula the whole time, terminated the agreement, walked off with the brand, and left BioLargo holding $3.763 million in unpaid receivables — $1.378 million in royalties and $2.385 million in product invoices — for which BioLargo established a full credit loss provision (10-Q, EDGAR 0001437749-26-028023). Some bastard built a pet-odor empire on BioLargo's work, reverse-engineered their way out of it, and ghosted a three-million-dollar bill. Q2 2026 revenue: $1.248 million. That is a fifty-five percent year-over-year collapse.

There are no confirmed near-term catalysts that change the math here, and that is worth saying plainly — there is not a goddamn hard-dated event in the next sixty days. Management mentioned an October consumer relaunch at their September 10 town hall — their own microphone, their own audience, no signed contract, no named distribution partner, not backed by inventory on order. The PFAS engineering business is genuinely growing. It is growing off a small base while the parent company burns through cash at a pace that makes slow organic growth irrelevant. ALREADY PRICED IN at eight cents.

The cash emergency is happening right now. $2.188 million in the account at June 30, 2026, against operating burn of $5.973 million in the first half of the year — roughly $3 million per quarter. At that pace the cash is gone in approximately 2.2 months. They survived H1 by raising $4.469 million through warrant exercises and subsidiary capital raises. Here is where that shit stops: the April 2026 warrant prospectuses show exercise prices from $0.19 to $0.33, weighted average around $0.265 (424B4 filings, EDGAR, April 2026). Every outstanding warrant is dead at $0.08. A new equity offering is coming because the math demands one, and existing shareholders take the dilution.

The balance sheet is broken everywhere you look. Stockholders' equity is negative $1.852 million. Working capital is negative $1.266 million. Enterprise value at verified net debt runs to roughly $29 million — nearly six times the annualized quarterly revenue run rate of about $5 million. Expensive as shit for a company with negative equity, no working capital, and a cash account ticking toward zero. Share count is 328.7 million and only goes higher. Institutional ownership is 0.036 percent.